Dr. Hesham Elhalawani, MD, MS

Dr. Elhalawani practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Elhalawani's NPI, 1508328402, was assigned on April 1, 2019. Dr. Elhalawani holds Massachusetts license 292409.

Dr. Elhalawani's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Elhalawani's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Elhalawani is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Elhalawani to 1 more hospital, 4 medical groups and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Elhalawani practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Elhalawani's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Elhalawani is licensed in Massachusetts.

CMS data shows 876 Medicare services from Dr. Elhalawani across 8 procedure codes in 2024, for 133 Medicare patients. Medicare paid $65,611 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 133 Medicare patients who saw Dr. Elhalawani in 2024. The largest group is 65 to 74, with 68 patients. 74% of them have cancer, and 68% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Elhalawani's median patient age at 73, with 40% women.

In 2020, Dr. Elhalawani wrote 12 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $142 in total drug cost.

Dr. Elhalawani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Elhalawani as offering telehealth.

Dmand AI links 81 papers to Dr. Elhalawani, published from 2014 to 2025. 2019 was the busiest year, with 12. The most frequent topics are Antineoplastic Agents, Brain Neoplasms and Randomized Controlled Trials as Topic. Dr. Elhalawani has published most often in Future Oncol. Dr. Elhalawani's most frequent co-authors are Clifton David Fuller, MD, Abdallah Sherif Radwan Mohamed, MD, MS, PhD and David I. Rosenthal, MD.

CMS Open Payments shows 2 general payments to Dr. Elhalawani from 1 drug or device company from 2024 to 2025. Honoraria make up the largest share, 100% of the total. IBA Proton Therapy, Inc. paid the most, $2,546.